Press release

DSM maintains positive momentum in challenging markets

Heerlen, NL, 05 Nov 2013 07:15 CET

  • DSM records 27% higher Q3 EBITDA compared to Q3 2012 (€342 million versus €270 million)
  • Life Sciences EBITDA up 23% from Q3 2012
  • Materials Sciences EBITDA up 27% from Q3 2012 
  • Q3 cash flow from operating activities €310 million, higher than Q3 2012
  • Core Earnings per Share Q3 2013 up 28% from Q3 2012
  • Outlook full year 2013 unchanged

Royal DSM, the Life Sciences and Materials Sciences company, today reported a third quarter EBITDA of €342 million compared to €270 million in Q3 2012. This improvement of 27% was realized despite an ongoing challenging macro-economic environment. 

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “I am pleased to report increased profitability in all our business clusters despite the initial impact from adverse currency movements and a continued challenging macro-economic environment. Nutrition continued its good performance notwithstanding some headwinds that emerged towards the end of Q3. Materials Sciences also delivered solid performance with higher profits.

Our focus remains on the full integration of acquisitions and delivery of synergies, which together with continued success in our wide-ranging Profit Improvement Program will help improve DSM’s returns. Current trading conditions are similar to those experienced at the end of Q3, while foreign exchange rates deteriorated. Nevertheless, we are firmly on track to deliver a significant increase in EBITDA for the full year. The 2013 outlook given at our Capital Markets Day remains unchanged.”

Key figures

Q3 2013 Q3 2012 +/- in € million volume price/mix exch. rates other
2,397 2,304 4% Net sales 5% -2% -4% 5%
1,061 945 12% Nutrition 5% -3% -4% 14%
183 172 6% Pharma 6% 4% -4%  
700 703 0% Performance Materials 6% -2% -3% -1%
374 384 -3% Polymer Intermediates 3% -3% -3%  
36 35 3% Innovation Center 0% 6% -3%  
43 65   Corporate Activities        
Q3 2013 Q3 2012 +/- in € million Jan - Sep 2013 Jan - Sep 2012 +/-
342 270 27% EBITDA 998 866 15%
242 202 20% Nutrition 706 589 20%
12 4 200% Pharma 34 26 31%
84 72 17% Performance Materials 246 228 8%
28 16 75% Polymer Intermediates 83 115 -28%
-4 -4   Innovation Center -11 -29  
-20 -20   Corporate Activities -60 -63  
148 111 33% Core net profit 433 378 15%
136 103 32% Net profit, before exceptional items 398 362 10%
117 81 44% Net profit, after exceptional items 348 267 30%
0.86 0.67 28% Core EPS (€/share) 2.53 2.29 10%
0.76 0.61 25% Net EPS before exceptional items, (€/share) 2.27 2.15 6%
0.65 0.47 38% Net EPS after exceptional items, (€/share) 1.98 1.57 26%
310 253   Cash flow from operations 463 547  
175 186   Capital expenditures (cash) 507 474  
      Net debt 2,043 1,668 *  

* year-end 2013

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more